Keyphrases
Sustained-release Implants
100%
Glaucoma Patients
100%
Phase III Clinical Trial
100%
Bimatoprost
100%
Intraocular Pressure
40%
Adverse Events
30%
Fellow Eye
30%
Primary Open-angle Glaucoma
20%
Low Incidence
10%
Repeated Administration
10%
Controlled Experiment
10%
Once-daily
10%
Change from Baseline
10%
Safety Profile
10%
Adult Patients
10%
Targeted Delivery
10%
Intraocular Pressure Reduction
10%
Dose-ranging
10%
Efficacy Profile
10%
Reduction Effect
10%
Eye Movement Control
10%
Safety Measures
10%
Sustained Delivery
10%
Intraocular Pressure Changes
10%
Glaucoma Treatment
10%
Pooled Study
10%
Topical Prostaglandin Analogues
10%
Medicine and Dentistry
Clinical Trial
100%
Sustained Drug Release
100%
Glaucoma
100%
Bimatoprost
100%
Intraocular Pressure
60%
Adverse Event
30%
Open Angle Glaucoma
20%
Implant
10%
Controlled Clinical Trial
10%
Prostaglandin Derivative
10%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Sustained Release
100%
Glaucoma
100%
Bimatoprost
100%
Adverse Event
30%
Open Angle Glaucoma
20%
Implant
10%
Controlled Clinical Trial
10%
Prostaglandin Analogue
10%
Veterinary Science and Veterinary Medicine
Bimatoprost
100%
Prostaglandin Analogue
10%